NeoPharm (Korea) Price Prediction
| 092730 Stock | KRW 11,950 10.00 0.08% |
Oversold Vs Overbought
42
Oversold | Overbought |
Using NeoPharm hype-based prediction, you can estimate the value of NeoPharm LTD from the perspective of NeoPharm response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in NeoPharm to buy its stock at a price that has no basis in reality. In that case, they are not buying NeoPharm because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
NeoPharm after-hype prediction price | KRW 11950.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
NeoPharm |
NeoPharm After-Hype Price Prediction Density Analysis
As far as predicting the price of NeoPharm at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NeoPharm or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NeoPharm, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
NeoPharm Estimiated After-Hype Price Volatility
In the context of predicting NeoPharm's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NeoPharm's historical news coverage. NeoPharm's after-hype downside and upside margins for the prediction period are 11,947 and 11,953, respectively. We have considered NeoPharm's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
NeoPharm is very steady at this time. Analysis and calculation of next after-hype price of NeoPharm LTD is based on 3 months time horizon.
NeoPharm Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as NeoPharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoPharm backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeoPharm, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.15 | 2.88 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
11,950 | 11,950 | 0.00 |
|
NeoPharm Hype Timeline
NeoPharm LTD is presently traded for 11,950on KOSDAQ of Korea. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. NeoPharm is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is presently at 0.15%. %. The volatility of related hype on NeoPharm is about 0.0%, with the expected price after the next announcement by competition of 11,950. About 39.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 576.0. NeoPharm LTD had not issued any dividends in recent years. The entity had 1:2 split on the 9th of September 2024. Assuming the 90 days trading horizon the next forecasted press release will be in 5 to 10 days. Check out NeoPharm Basic Forecasting Models to cross-verify your projections.NeoPharm Related Hype Analysis
Having access to credible news sources related to NeoPharm's direct competition is more important than ever and may enhance your ability to predict NeoPharm's future price movements. Getting to know how NeoPharm's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NeoPharm may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| 058400 | Korea New Network | 0.00 | 0 per month | 1.34 | 0.08 | 4.09 | (2.96) | 13.77 | |
| 040910 | ICD Co | 0.00 | 0 per month | 0.00 | (0.18) | 5.05 | (4.45) | 13.57 | |
| 104460 | DYPNF CoLtd | 0.00 | 0 per month | 3.29 | 0.01 | 7.09 | (4.93) | 20.23 | |
| 351320 | Solution Advanced Technology | 0.00 | 0 per month | 2.90 | (0.03) | 5.42 | (5.54) | 20.21 | |
| 011390 | Busan Industrial Co | 0.00 | 0 per month | 3.00 | 0.16 | 10.02 | (4.82) | 43.62 | |
| 011390 | Busan Ind | 0.00 | 0 per month | 3.00 | 0.16 | 10.02 | (4.82) | 43.62 | |
| 000250 | Sam Chun Dang | 0.00 | 0 per month | 0.00 | (0.13) | 6.20 | (6.49) | 17.04 | |
| 115160 | Humax Co | 0.00 | 0 per month | 0.00 | (0.34) | 3.14 | (5.69) | 10.50 | |
| 133820 | Finebesteel | 0.00 | 0 per month | 2.11 | 0.07 | 3.59 | (3.69) | 25.82 | |
| 500003 | Shinhan Inverse WTI | 0.00 | 0 per month | 0.00 | (0.08) | 2.89 | (2.76) | 9.15 |
NeoPharm Additional Predictive Modules
Most predictive techniques to examine NeoPharm price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NeoPharm using various technical indicators. When you analyze NeoPharm charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About NeoPharm Predictive Indicators
The successful prediction of NeoPharm stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NeoPharm LTD, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NeoPharm based on analysis of NeoPharm hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NeoPharm's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NeoPharm's related companies.
Story Coverage note for NeoPharm
The number of cover stories for NeoPharm depends on current market conditions and NeoPharm's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NeoPharm is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NeoPharm's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
NeoPharm Short Properties
NeoPharm's future price predictability will typically decrease when NeoPharm's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NeoPharm LTD often depends not only on the future outlook of the potential NeoPharm's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeoPharm's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.8 M | |
| Cash And Short Term Investments | 105 B |
Complementary Tools for NeoPharm Stock analysis
When running NeoPharm's price analysis, check to measure NeoPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoPharm is operating at the current time. Most of NeoPharm's value examination focuses on studying past and present price action to predict the probability of NeoPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoPharm's price. Additionally, you may evaluate how the addition of NeoPharm to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |